Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
13.66
-0.50 (-3.53%)
At close: Nov 20, 2026, 4:00 PM EST
13.70
+0.04 (0.29%)
After-hours: Nov 20, 2026, 7:30 PM EST
Mineralys Therapeutics Employees
Mineralys Therapeutics had 76 employees as of December 31, 2025. The number of employees increased by 25 or 49.02% compared to the previous year. That makes Mineralys Therapeutics the 33,002nd largest employer in the world and 4,286th in the United States.
Employees
76
Change (1Y)
25
Growth (1Y)
49.02%
Revenue / Employee
n/a
Profits / Employee
-$4,868,053
Market Cap
1.21B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | 25 | 49.02% |
| Dec 31, 2024 | 51 | 23 | 82.14% |
| Dec 31, 2023 | 28 | 16 | 133.33% |
| Dec 31, 2022 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| MannKind | 592 |
| Ocular Therapeutix | 325 |
| Structure Therapeutics | 281 |
| Taysha Gene Therapies | 99 |
| Silence Therapeutics | 88 |
| Vor Biopharma | 76 |
| GH Research | 73 |
MLYS News
- 10 days ago - Mineralys Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 11 days ago - Mineralys Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 13 days ago - Mineralys Therapeutics announces long-term results from Transform-HTN trial - TheFly
- 13 days ago - Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026 - GlobeNewsWire
- 15 days ago - Mineralys Therapeutics price target lowered to $19 from $29 at UBS - TheFly
- 16 days ago - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Mineralys Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 17 days ago - Mineralys Therapeutics Earnings release: Q3 2026 - Filings